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Abstract 15 
Mycoplasma pneumoniae is a major human respiratory pathogen causing both upper and 16 
lower respiratory disease in humans of all ages, and can also result in other serious extra-17 
pulmonary sequelae. A multi-locus sequence typing (MLST) scheme for M. pneumoniae was 18 
developed, based on the sequence of eight housekeeping genes (ppa, pgm, gyrB, gmk, glyA, 19 
atpA, arcC, and adk) and applied to 55 M. pneumoniae clinical isolates and the two type 20 
strains M129 and FH. A total of 12 sequence types (STs) resulted for 57 M. pneumoniae 21 
isolates tested; with a discriminatory index of 0.21 STs per isolate. The MLST loci used in 22 
this scheme were shown to be stable in ten strains following ten sequential sub-culture 23 
passages. Phylogenetic analysis of concatenated sequences of the eight loci indicated two 24 
distinct genetic clusters which could be directly linked to multi-locus variable-number 25 
tandem repeat analysis (MLVA) type. Genetic MLST clustering was confirmed by genomic 26 
sequence analysis, indicating that the MLST scheme developed in this study is representative 27 
of the genome. Furthermore, this MLST scheme was shown to be more discriminatory than 28 
both MLVA and P1 typing for the M. pneumoniae isolates examined, providing a method for 29 
further and more detailed analysis of observed epidemic peaks of M. pneumoniae infection. 30 
This scheme is supported by a public web-based database 31 
(http://pubmlst.org/mpneumoniae). 32 
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Introduction 33 
Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP) 34 
transmitted by aerosol or close contact (1). M. pneumoniae may cause other serious extra-35 
pulmonary sequelae such as encephalitis (2). The pathogen is found in all age groups, with 36 
higher prevalence in children aged 5-14 years (3, 4). Admissions to a UK hospital in patients 37 
with CAP that were attributed to M. pneumoniae were estimated at 18% in 1982 and 4% in 1999 38 
(5). Major increases and decreases in M. pneumoniae infection have occurred periodically in the 39 
United Kingdom; historically, epidemics have occurred at approximately four yearly intervals 40 
and have lasted 12-15 months, concurrent with sporadic infection at a lower level and seasonal 41 
peaks December to February (4, 6). However, globally, peaks of infection have been observed in 42 
either summer or autumn, with no obvious explanation for this seasonal variation (7-10). 43 
Typing of clinical isolates by molecular methods is of importance for the understanding of the 44 
epidemiology of M. pneumoniae infection and for analysis of endemic outbreaks. It is generally 45 
considered that molecular typing of M. pneumoniae is hampered by the fact that the pathogen is 46 
a genetically homologous species (11).  Initial molecular typing targeted the gene encoding the 47 
major surface protein (P1) of M. pneumoniae. PCR-restriction fragment length polymorphism 48 
(RFLP) analysis of the P1 gene, encoding a major adhesion, is the most common genotyping 49 
method. This enables the separation of isolates into two types, type 1 and 2 (11-13). More recent 50 
studies utilise the repetitive regions, RepMp2/3 and RepMp4 which can be found in the P1 gene, 51 
for molecular typing and have resulted in the identification of an additional subtype and three 52 
variants of these subtypes (14, 15). Multi-locus variable-number tandem-repeat (VNTR) analysis 53 
(MLVA) has also been used, based on the variation in the copy number of tandem repeated 54 
sequences, called VNTRs, found at different loci across the genome. The variation of the copy 55 
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number of these tandem repeats (TRs) depends on the isolate tested. Initially, 265 strains were 56 
grouped into twenty-six MLVA types, based on five VNTR loci (Mpn1, Mpn13-16) and an 57 
additional 18 novel types have since been reported (16-18). However, locus Mpn1 is unstable in 58 
both clinical strains and in laboratory passages, and most of the novel types came from variations 59 
in Mpn1, therefore there is international consensus that this locus should be removed from the 60 
typing scheme (19).  61 
Multi-locus sequence typing (MLST) was previously attempted for the molecular typing of 62 
M. pneumoniae however, due to the homogeneity of the M. pneumoniae species, very little 63 
polymorphism was found in the housekeeping genes examined and it was previously concluded 64 
that the use of an MLST with housekeeping and structural genes was not useful for molecular 65 
typing (20). Only three housekeeping genes were thoroughly examined for polymorphisms 66 
across 30 isolates of either P1 type 1, 2, or a variant strain. The other genes selected for analysis 67 
were examined against a single representative strain from each subtype. In this study an MLST 68 
scheme was developed with a high discriminatory ability to differentiate M. pneumoniae isolates 69 
based on sequence polymorphisms within eight housekeeping genes, improving on all published 70 
typing methods for M. pneumoniae. 71 
Materials and Methods 72 
Mycoplasma pneumoniae strains, culture conditions and sample preparation The strains 73 
analysed in this study are listed in Table 1. Fifty five M. pneumoniae strains were submitted to 74 
Public Health England, UK for clinical diagnostic purposes and the two M. pneumoniae type 75 
strains, FH (NCTC 10119; ATCC 15531) and M129 (ATCC 29342) were obtained from 76 
National Collection of Type Cultures (NCTC; held by Public Health England). All strains were 77 
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triple cloned on Mycoplasma Agar (Mycoplasma Experience; Surrey, UK) and confirmed as M. 78 
pneumoniae by amplification of p1 gene (21). 79 
All strains were subsequently cultured in Mycoplasma Liquid Medium (MLM; Mycoplasma 80 
Experience; Surrey, UK). For genomic sequencing, strains were grown in 100 ml broth culture 81 
and the genomic DNA was extracted using the GenEluteTM Bacterial Genomic DNA Kit (Sigma; 82 
Dorset, UK). PCR amplification was performed on bacterial DNA from a 500 µl, four day 83 
culture that was released by boiling lysis (95°C for 10 minutes) following centrifugation at 84 
17000 xg for 10 minutes, removal of all MLM, and re-suspension in 50 µl sterile water. 85 
Multi-locus Sequence Typing Housekeeping genes considered conserved in other bacterial 86 
species under a low rate of selective pressure were chosen for analysis (Table 2). Locus 87 
sequences were selected using the available genome sequences of M. pneumoniae FH and M129 88 
(FH: NC_017504.1; M129: NC_000912.1) and available whole genome sequence of 35 clinical 89 
isolates. Ten genes were included for initial analysis: recA protein (recA), inorganic phosphatase 90 
(ppa), phosphoglycerate mutase (pgm), DNA gyrase subunit B (gyrB), guanylate kinase (gmk), 91 
serine hydroxymethyltransferase (glyA), elongation factor P (efp), ATP synthase subunit α 92 
(atpA), carbamate kinase (arcC), and adenylate kinase (adk); however, recA and efp were 93 
excluded from the resulting MLST scheme. Locus regions for PCR amplification were selected 94 
based on areas of the CDS containing nucleotide polymorphisms. 95 
PCR utilising the primers listed in Table 3 were used to amplify the target genes from a further 96 
20 M. pneumoniae clinical isolates. Amplification of each of the locus sequences were 97 
performed in a DNA thermocycler (Techne Prime; Stone, UK) in 50 µl reactions containing: 98 
1 x GoTaq Fexi Buffer (Promega; Southampton, UK), 1.5 mM MgCl2, 0.2 mM deoxynucleoside 99 
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triphosphates, 0.5 pmol/µl of each primer, 1.56 units of GoTaq DNA Polymerase (Promega; 100 
Southampton, UK), and 2.5 µl template DNA. PCR reactions consisted of an initial denaturation 101 
step of three minutes at 94°C, followed by 35 cycles of 60 seconds at 94°C, 60 seconds at 60°C 102 
and 60 seconds at 72°C. A final extension step was maintained for 10 minutes at 72°C. Primer 103 
sequences and PCR product sizes are shown in Table 3. The PCR products were analysed on 104 
1.5% agarose gels with ethidium bromide visualisation. All PCR reactions were performed in 105 
duplicate. 106 
PCR amplicons were purified using a Qiagen MiniPrep kit (Qiagen Inc.; Hilden, Germany) as 107 
per manufacturer’s instructions and sequenced using the amplification primers, performed by 108 
MWG Eurofins (Ebersberg, Germany). The sequences obtained from each corresponding 109 
forward and reverse primer were assembled and trimmed for double-stranded, high quality 110 
sequence. All the sequences obtained for each locus were aligned using ClustalW (Vector NTI; 111 
Paisley, UK) and different allelic types (AT; sequences with at least a one-nucleotide difference) 112 
were assigned sequential numbers. The combination of the eight alleles determined a strain’s 113 
allelic profile, and each unique allelic profile was designated a unique sequence type (ST). Open-114 
reading frame amino acid sequences were identified using Expasy translation tool (mycoplasma 115 
setting; web.expasy.org/translate/) for each AT. Deduced amino acid sequences were aligned 116 
using ClustalW (Vector NTI; Paisley, UK) for each locus and synonymous changes were 117 
identified. 118 
MLVA and P1-typing MLVA type was determined as described by Dégrange et al. (16), 119 
excluding the VNTR locus Mpn-1 and using international nomenclature consensus (19). P1 type 120 
was determined as described by Dumke et al. (15). 121 
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Genomic sequencing Genomic sequence data for 35 isolates was obtained using the Illumina 122 
Nextera XT sample prep kit (Illumina; Cambridge, UK) and sequenced on an Illumina HiSeq 123 
2500 platform with TruSeq Rapid SBS kits (200 cycles; Illumina) and cBOT for cluster 124 
generation (Illumina). Fastq reads were trimmed using trimmomatic 0.32 with the parameters: 125 
LEADING: 30; TRAILING: 30; SLIDINGWINDOW: 10:30; MINLEN: 50 (20). Illumina reads 126 
were assembled to the M129 type strain (NC_000912.1) using SPAdes version 2.5.0 (21) and 127 
mapped to M129 using Genious® version 8.0.4. Sequencing yielded at least one contig of 128 
between 99,047 bp and 324,397 bp with homology to M129 type strain (NC_000912.1) passing 129 
quality and coverage checks. Identity as M. pneumoniae from genomic data was confirmed with 130 
16S rRNA sequence analysis. Illumina reads for all the isolates were mapped against the 131 
reference chromosome M129 (EMBL accession code U00089) using SMALT 132 
(http://www.sanger.ac.uk/resources/software/smalt/) in order to identify SNPs as previously 133 
described (22). Regions of recombination in the whole chromosomes of the isolates were 134 
analysed for using Genealogies Unbiased By recomBinations In Nucleotide Sequences 135 
(GUBBINS) (23).  136 
Phylogenetic analysis The locus sequences corresponding to each strain were concatenated 137 
head-to-tail for diversity analysis. Sequence analyses and tree construction were performed using 138 
MEGA 6.0. Neighbour-joining trees were constructed for each individual locus and concatenated 139 
sequences using Kimura’s two-parameter model (26, 27). Maximum-likelihood trees were 140 
constructed for each individual locus using the Jukes-Cantor model of sequence evolution (28). 141 
Maximum-likelihood trees were constructed from concatenated sequences of the eight MLST 142 
loci using the generalised time-reversible (GTR) model of sequence evolution with uniform rates 143 
of variation (29). Bootstrap analyses with 1000 replicates were performed for every phylogenetic 144 
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tree (30). Relatedness between STs was analysed based on allelic profiles using eBURST 145 
version3. Maximum-likelihood trees were constructed from genomic sequences after the removal 146 
of areas of recombination. In total 1854 SNP sites were identified in comparison to the M129 147 
reference chromosome. Three regions were predicted to contain SNP sites that had arisen by 148 
recombination, and these contained 28 SNP sites. 149 
Results 150 
MLST of M. pneumoniae Initial examination of ten gene targets in the two type strains M129 151 
and FH and genomic sequence from 35 M. pneumoniae clinical isolates identified variation, SNP 152 
differences, in eight out of the ten genes. Genes recA and efp were 100% conserved in all 153 
sequences analysed and were therefore excluded from the MLST scheme. Genomic sequence 154 
analysis and additional PCR and sequencing of a further 20 clinical isolates of all eight targets 155 
resolved a total of 12 STs. The discriminatory typing ability for M. pneumoniae was 0.21 ST per 156 
isolate. The number of SNPs observed within each individual locus and the percentage of 157 
polymorphic sites are indicated in Table 3, with pgm having the highest number of SNPs (10 158 
SNPs) and the highest percentage of polymorphic sites corrected for sequence length (0.93%). 159 
The number of alleles per locus ranged from two (ppa, gyrB, gmk and arc) to four (atpA) (Table 160 
3). Examination of the Hunter-Gaston diversity index (DI; which ranges from 0.0 = no diversity 161 
to 1.0 = complete diversity) indicated moderate diversity between the STs (DI: 0.784; 95% CI: 162 
0.716-0.852) with the greatest individual diversity shown in pgm (DI: 0.620; 95% CI: 0.566-163 
0.674) and the lowest diversity in arcC (DI: 0.069; 95% CI: 0.000-0.158).  164 
Neighbour-joining and maximum-likelihood trees constructed from concatenated sequences of 165 
the eight loci for the 57 M. pneumoniae isolates (Figure 1) illustrated two genetically distinct 166 
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clusters which were confirmed by eBURST examination of relatedness (Figure 2). The two 167 
clusters, clonal complexes (CC) designated CC1 and CC2, contained ST1, ST3, ST5, ST9 and 168 
ST11, and ST2, ST4, ST6, ST7, ST8 and ST10, respectively. ST12 located distal to the two main 169 
clusters, however, phylogenetic analysis revealed closer positioning to CC1. Neighbour-joining 170 
and maximum-likelihood trees were constructed for the eight loci individually (data not shown) 171 
and topology of both neighbour-joining and maximum-likelihood trees was consistent for all loci 172 
and concatenated sequences. 173 
Five homogenous strains (MPN13-MPN17) originating from nose and throat swabs of the same 174 
patient with Stevens-Johnson syndrome had identical STs (ST3). Additionally, two clinical 175 
isolates (MPN104 and MPN106) originating from separate sputum samples from a patient with 176 
bronchopneumonia taken four days apart also had identical STs (ST4). This indicates a single, 177 
clonal population responsible for infection in these cases.  178 
The possibility of synonymous sequence changes (indicating a pressure to conserve amino acid 179 
sequence and protein structure) was investigated by comparing predicted translated sequences 180 
for each locus. Analysis of deduced amino acid sequences of the eight loci for the 57 strains 181 
indicated that both synonymous and non-synonymous SNPs occurred of which approximately 182 
44% resulted in an amino acid change. Non-synonymous SNPs are highlighted in Figure A2. 183 
Amino acid sequences for ArcC, Gmk and GyrB yielded homologous sequences for all ATs, 184 
numbering at two ATs for each locus. In comparison, Pgm analysis resulted in the largest 185 
number of non-synonymous changes in amino acid sequence, with four changes in the sequence 186 
between three ATs.  187 
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The MLST scheme was applied to the published complete genome sequences of M. pneumoniae 188 
available from NCBI: 309 (NC_016807.1), M129-B7 (CP003913.2), M29 (NZ_CP008895.1), 189 
PO1 (GCA_000319655.1), PI 1428 (GCA_000319675.1) and 19294 (GCA_000387745.1). 190 
These strains were determined as ST2, ST1, ST3, ST2, ST1 and ST7, respectively. 191 
The stability of each MLST locus was assessed in ten M. pneumoniae isolates. Isolates were re-192 
typed following short-term passage (ten sequential sub-culture passages) in liquid medium. All 193 
loci were found to be completely stable, with no SNPs in comparison to the original isolate.  194 
Genomic sequence analysis Three regions of SNPs were predicted to have arisen by 195 
homologous recombination in the chromosomes of the 35 clinical M. pneumoniae isolates 196 
(Figure 3); one of which distinguished the genomic clade (GC) GC1 from GC2; and the other 197 
two occur within GC1. Area one was predicted to occur in all strains in GC1, area two in ten 198 
strains, and a single strain MPN113 had a single additional predicted area of recombination, area 199 
3. Following removal of predicted areas of recombination two distinct genetic clades were 200 
identified, GC1 and GC2 (Figure 3). Excellent parity was found using this method and 201 
concatenated MLST sequences with all strains co-locating to the corresponding CC and GC.    202 
Comparison to other typing methods There was no obvious link between the MLST ST and 203 
the year when the strains were collected, the patient’s age and the sample origin; however, 204 
limited numbers of strains were available per year and for some years there were no strains. 205 
Indeed, multiple STs can be observed in a single year. Furthermore, MLST ST was unrelated to 206 
P1 type, with multiple P1 types observed within a ST (Table 1). However, in the two most 207 
common STs, the majority strains were P1 type 2 and P1 type 1 for ST2 and ST3 respectively. In 208 
comparison, this MLST scheme was more comparable to MLVA typing. The two major clusters 209 
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observed, CC1 and CC2, could be directly linked to MLVA type; CC1 contained MLVA type 210 
4572 whereas CC2 contained MLVA types 3662 and 3562. Each ST contained only one MLVA 211 
type with the exception of ST2 which contained both 3662 and 3562 and ST11 which contained 212 
4572, 3662 and 3562 (Table 1). Distribution of MLVA type, P1 type and MLST ST can be 213 
observed in Figure 4, indicating that P1 type 1, MLST ST2 and MLVA types 3662 and 4572 214 
were the most frequently occurring in the isolates tested.  215 
In the isolates tested in this scheme, MLST was deemed to be more discriminatory than both 216 
MLVA typing and P1 typing; resulting in 0.21, 0.05 and 0.07 types per isolate, respectively. This 217 
was confirmed by examination of Hunter-Gaston DI indicating larger discriminatory ability for 218 
the MLST scheme (DI: 0.784; 95% CI: 0.716-0.852) than the current MLVA scheme (DI: 0.633; 219 
95% CI: 0.583-0.683) and P1 typing (DI: 0.551; 95% CI: 0.485-0.617). 220 
Online database A Mycoplasma pneumoniae MLST online database was created for both 221 
MLST allele and profile definitions and isolate data (31); website 222 
http://pubmlst.org/mpneumoniae 223 
Discussion 224 
MLST has been used to genotype several species of bacteria, including several mycoplasma 225 
species; Mycoplasma agalactiae, Mycoplasma bovis and Mycoplasma hyorhinis (32-34). This 226 
study has described the successful development of a novel M. pneumoniae MLST scheme to 227 
allow the characterisation of clinical isolates. This scheme was successfully used to discriminate 228 
55 clinical isolates of M. pneumoniae from British patients (with the exception of two USA 229 
isolates) within the reference laboratory collection, from respiratory and extra-pulmonary sites 230 
and the two type strains M129 and FH. Eight housekeeping genes were identified as suitable 231 
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targets for the scheme and these were used to genotype M. pneumoniae isolates by either PCR 232 
followed by sequencing or whole genome sequence analysis. gyrB contains a quinolone 233 
resistance-determining region (QRDR) with documented in vitro mutations at amino acid 234 
positions 443, 464 and 483. Clinical use of quinolones may increase selective pressure in vivo 235 
resulting in a high mutation rate (35). However, the gyrB locus sequence amplified in this MLST 236 
scheme is in a different region of the gene from the QRDR and is therefore considered a suitable 237 
MLST target. The stability of the eight loci was evaluated in vitro and was confirmed before and 238 
after ten repeated passages of ten strains in liquid medium. However, stability over a larger 239 
number of passages in liquid medium and evaluation of stability using in vitro tissue culture was 240 
not assessed.   241 
The discriminatory power of this MLST scheme with the eight loci was 0.784 for the collection 242 
of 57 isolates. In comparison, the Hunter-Gaston DI of the P1-typing method for the 57 isolates 243 
was 0.551 and the DI of the MLVA scheme was 0.633; therefore this MLST scheme was more 244 
discriminatory for the isolates tested. However, it has previously been shown that the established 245 
MLVA method is more discriminatory than P1 typing (16), confirmed in this study. The allelic 246 
diversity of each of the MLST loci varied significantly at each locus, with the pgm, glyA, atpA, 247 
gyrB, gmk and ppa loci being more discriminatory than the adk and arcC loci. The association of 248 
this set of markers with variable Hunter-Gaston DIs makes this MLST, in theory, more optimal 249 
for epidemiological studies than other existing methodologies. 250 
Analysis of M. pneumoniae infection at an individual patient level was possible using this 251 
scheme. Multiple clinical isolates were available from two of 50 patients: five from a patient 252 
with Stevens-Johnson syndrome (MPN013-MPN017) and two from a patient with 253 
bronchopneumonia taken four days apart. In both cases the MLST ST, MLVA type and P1 type 254 
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remained the same, indicating a single clonal isolate was responsible for infection. Recurring or 255 
re-infection of M. pneumoniae could be determined using this scheme. Recurring infection 256 
would have the same ST as the original infection whereas re-infection with M. pneumoniae 257 
would likely be a different ST. Genetic MLST instability in isolates could occur however, in this 258 
study this was not seen over ten passages. 259 
The eBURST analysis illustrates the relationship of STs on the basis on the number of MLST 260 
loci that differ between two STs. Analysis of this population modelling indicates that the two 261 
clusters, CC1 and CC2, differed by more than one locus, but within each cluster the STs did not 262 
differ by more than one locus. Within a cluster, this highlights the homogenous nature of the 263 
M. pneumoniae species, however a definitive split can be observed between the two clusters in 264 
both MLST ST and MLVA type. A possible divergent clade with ST12 from CC1 is also 265 
apparent, however more isolates need to be typed by this method to confirm this observation. 266 
Few typing methods have previously been able to detect significant differences between strains, 267 
including one previous attempt to subtype M. pneumoniae by MLST with housekeeping and 268 
structural genes (12, 15, 22). The previous MLST was determined to be not sufficiently 269 
discriminatory to be used for epidemiological purposes. However, the MLST scheme developed 270 
in this study was able to discriminate between M. pneumoniae isolates and resulted in two 271 
genetically distinct clusters, indicating significant differences between strains. 272 
Comparison between genomic sequence analysis after the removal of predicated areas of 273 
recombination and phylogenetic analysis of concatenated MLST sequences showed similar 274 
topology and the same distinct genetic clustering. This indicates that this MLST scheme is 275 
representative of the genome and confirms M. pneumoniae can be subdivided into two distinct 276 
genetic lineages. 277 
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Typing of clinical M. pneumoniae isolates is becoming increasingly important due to the global 278 
increase in M. pneumoniae infections and the increase in macrolide-resistant strains (36, 37). 279 
This scheme provides a more discriminatory method than both the MLVA and P1 typing 280 
methods currently in use, allowing further and more detailed analysis of observed epidemic 281 
peaks of M. pneumoniae infection. Community outbreaks of pneumonia caused by M. 282 
pneumoniae have been described worldwide (38-40), and it would be interesting to evaluate this 283 
MLST scheme in such epidemic situations. The level of discrimination of this typing method and 284 
usefulness in epidemic analysis should be confirmed by comparing outbreak-related strains to a 285 
set of control strains that were isolated from a similar time period and geographical area but that 286 
are not epidemiologically related. More severe or adverse infections with M. pneumoniae are 287 
seen in some patients. The reason for this is not clear however, it can be postulated that this is 288 
due to specific microbe pathogenicity (identified through genetic markers) or variance in host 289 
susceptibility. This method could assist in determining if this is a strain specific phenomenon. 290 
One advantage of MLST is that it is PCR based and does not require the growth of bacteria, 291 
which can be a lengthy process for M. pneumoniae and it does not limit investigation through 292 
requirement of specialist methodology. However, there is a large amount of sequencing required 293 
for this method which can be laborious and expensive; therefore, adaptation for wide-spread use 294 
directly on clinical specimens would be beneficial. 295 
In conclusion, this study presents a robust MLST scheme that has proven discriminatory for 296 
M. pneumoniae, providing isolate characterisation and a higher level of discrimination than 297 
MLVA and P1-typing methods. In addition, phylogenetic analysis of both MLST STs and whole 298 
genome sequence data revealed two genetically distinct clusters. Crucially, this scheme for 299 
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M. pneumoniae is also supported by a public web-based database 300 
(http://pubmlst.org/mpneumoniae).  301 
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Table 1. Description of Mycoplasma pneumoniae strains used in this study, their sequence type (ST) and allelic profile, 
and their MLVA and P1 types. Strains isolated from the same patient are indicated by grey shading. 
Strain Year of 
isolation 
Country of 
isolation 
Isolation site ST Allelic profile MLVA 
type 
P1 type 
     ppa pgm gyrB gmk glyA atpA arcC adk   
M129 (ATCC 
29342) 
1969 USA Unknown 1 1 2 1 1 1 3 2 1 4572 1 
MPN135 1986 USA Unknown 1 1 2 1 1 1 3 2 1 4572 V1 
FH (ATCC 
15531) 
1944 USA Sputum 2 2 3 2 2 2 4 1 1 3662 2 
MPN007 1978 UK Throat swab 2 2 3 2 2 2 4 1 1 NTa 1 
MPN021 1983 UK Unknown 2 2 3 2 2 2 4 1 1 3662 NTa 
MPN022 2010 UK Sputum 2 2 3 2 2 2 4 1 1 3562 2c 
MPN023 1983 UK Sputum 2 2 3 2 2 2 4 1 1 3662 2 
MPN101 1978 UK Unknown 2 2 3 2 2 2 4 1 1 3562 1 
MPN102 1981 UK Brain frontal lobe 2 2 3 2 2 2 4 1 1 3662 2 
MPN107 1983 UK Sputum 2 2 3 2 2 2 4 1 1 3562 1 
MPN114 1983 UK Sputum 2 2 3 2 2 2 4 1 1 3662 1 
MPN117 1982 UK Sputum 2 2 3 2 2 2 4 1 1 3562 2 
MPN119 1982 UK Sputum 2 2 3 2 2 2 4 1 1 3562 2 
MPN121 1983 UK Sputum 2 2 3 2 2 2 4 1 1 3662 2c 
MPN123 1983 UK Sputum 2 2 3 2 2 2 4 1 1 3662 2 
MPN125 1983 UK Sputum 2 2 3 2 2 2 4 1 1 3562 2 
MPN126 1979 UK Unknown 2 2 3 2 2 2 4 1 1 3662 2 
MPN128 1976 USA Unknown 2 2 3 2 2 2 4 1 1 3662 1 
MPN132 1982 UK Sputum 2 2 3 2 2 2 4 1 1 3562 2 
MPN133 1982 UK Sputum 2 2 3 2 2 2 4 1 1 3662 2 
MPN134 1982 UK Sputum 2 2 3 2 2 2 4 1 1 3662 2 
MPN005 1983 UK Sputum 3 1 2 1 1 1 3 1 1 4572 1 
MPN006 1982 UK Sputum 3 1 2 1 1 1 3 1 1 4572 NTa 
MPN013 2009 UK Nose & throat swabs 3 1 2 1 1 1 3 1 1 4572 1 
MPN014 2009 UK Nose & throat swabs 3 1 2 1 1 1 3 1 1 4572 1 
MPN015 2009 UK Nose & throat swabs 3 1 2 1 1 1 3 1 1 4572 1 
MPN016 2009 UK Nose & throat swabs 3 1 2 1 1 1 3 1 1 4572 1 
MPN017 2009 UK Nose & throat swabs 3 1 2 1 1 1 3 1 1 4572 1 
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MPN020 1982 UK Sputum 3 1 2 1 1 1 3 1 1 4572 2 
MPN103 1982 UK Sputum 3 1 2 1 1 1 3 1 1 4572 1 
MPN105 1983 UK Sputum 3 1 2 1 1 1 3 1 1 4572 1 
MPN108 1983 UK Sputum 3 1 2 1 1 1 3 1 1 4572 1 
MPN109 1982 UK Sputum 3 1 2 1 1 1 3 1 1 4572 2 
MPN113 1967 UK Unknown 3 1 2 1 1 1 3 1 1 4572 1 
MPN116 1982 UK Sputum 3 1 2 1 1 1 3 1 1 4572 1 
MPN118 1996 UK Sputum 3 1 2 1 1 1 3 1 1 4572 1 
MPN120 1982 UK Sputum 3 1 2 1 1 1 3 1 1 4572 1 
MPN122 1982 UK Sputum 3 1 2 1 1 1 3 1 1 4572 1 
MPN136 1982 UK Sputum 3 1 2 1 1 1 3 1 1 4572 1 
MPN004 1981 UK Sputum 4 2 1 2 2 2 4 1 1 3662 1 
MPN104 1981 UK Sputum 4 2 1 2 2 2 4 1 1 3662 2 
MPN106 1981 UK Sputum 4 2 1 2 2 2 4 1 1 3662 2 
MPN110 1981 UK Sputum 4 2 1 2 2 2 4 1 1 3662 2 
MPN124 1981 UK Sputum 4 2 1 2 2 2 4 1 1 3662 2 
MPN131 1981 UK Sputum 4 2 1 2 2 2 4 1 1 3662 1 
MPN111 1968 UK Unknown 5 1 2 1 1 1 2 1 1 4572 1 
MPN011 1983 UK Sputum 6 2 3 2 2 2 1 1 1 3662 1 
MPN112 1983 UK Sputum 6 2 3 2 2 2 1 1 1 3662 1 
MPN127 1982 UK Sputum 7 2 3 2 2 2 4 1 2 3662 2 
MPN129 1983 UK Sputum 8 2 3 2 2 2 4 1 3 3662 2 
MPN130 1983 UK Sputum 9 1 2 1 1 1 3 1 4 4572 1 
MPN008 1981 UK Sputum 10 2 1 2 2 2 4 1 2 3662 2 
MPN018 1981 UK Sputum 10 2 1 2 2 2 4 1 2 3662 2 
MPN010 1983 UK Sputum 11 1 2 1 1 3 3 1 1 3662 1 
MPN003 1983 UK Sputum 11 1 2 1 1 3 3 1 1 4572 1 
MPN012 1981 UK Brain cyst 11 1 2 1 1 3 3 1 1 3562 NTa 
MPN019 1983 UK Sputum 12 2 2 1 1 3 3 1 4 4572 1 
aNT M. pneumoniae not classified by MLVA/P1 typing 
 445 
 446 
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Table 2. MLST loci used in established bacterial MLST schemes also present in M. pneumoniae. 
Bacterial Species MLST Loci a 
 reca ppa pgm gyrb gmk glya efp atpa arcc adk 
Bacillus cereus           
Chlamydia trachomatis           
Campylobacter jejuni           
Escherichia coli           
Enterococcus faecium           
Haemophilus influenzae           
Helicobacter pylori           
Moraxella catarrhalis           
Neisseria meningitidis           
Staphylococcus aureus           
Staphylococcus epidermidis           
Streptococcus suis           
Vibrio vulnificus           
Yersinia pseudotuberculosis           
a MLST loci were chosen based on the frequency of use in other bacterial MLST schemes  
(http://www.mlst.net/) and the presence of the gene in the published M129 and FH whole genomes. 
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Table 3. Primer pairs developed in this study and variability of the different loci. 
Name  Primer sequence (5’-3’) Amplicon 
(bp) 
MLST 
locus 
location 
No. of 
alleles 
No. 
polymorphic 
sites 
% 
polymorphic 
sites 
Average G + 
C content 
(%) 
Hunter-Gaston 
Diversity Index 
a 
95% 
Confidence 
Interval 
ppa F CGCTGACCAAGCCTTTCTAC 256 192-440 2 1 0.39 38.4 0.501 0.470-0.533 
 R CACTCCAAACTTTGCACTCCC         
pgm F AGCACCTTGCACGATGAAGA 1072 456-1652 3 10 0.93 43.7 0.620 0.566-0.674 
 R CCTGCGCCTTCGTTAATTGG         
gyrB F TTGTCCCGGACTTTACCGTG 429 524-952 2 2 0.47 39.9 0.505 0.482-0.528 
 R TGTTTTCGACAGCAAAGCGG         
gmk F GAGCGGTGTTGGCAAAAGTA 394 189-582 2 1 0.25 40.1 0.505 0.482-0.528 
 R TGCATCCTCGTCATTACGCTT         
glyA F CAGAGAACTATGTGAGTAGGGACA 676 74-749 3 2 0.30 45.6 0.560 0.493-0.627 
 R TGACAACCCGGAAAGACACC         
atpA F GTCGCTGATGGCATTGCTAAG 796 100-895 4 3 0.38 44.8 0.557 0.502-0.612 
 R CCAGTAAACGCGAGTGCAAG         
arcC F CCCCATCAAGCCGTGTACTT 570 304-873 2 1 0.18 45.5 0.069 0.000-0.158 
 R TTGGGCAATAATGGCCGTCT         
adk F GTAGCCAACACCACCGGATT 473 70-542 4 3 0.63 47.5 0.199 0.063-0.335 
 R ACGGTGTCTTCGTAAAGCGT         
a Hunter-Gaston diversity index (DI, ranges from 0.0 indicates no diversity to 1.0 indicates complete diversity) 
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Figure Legends 447 
Figure 1. Phylogenetic trees based on concatenated sequences of 8 MLST loci. 448 
Phylogenetic trees were constructed based on concatenated sequences of eight housekeeping 449 
loci for 12 unique STs using Maximum likelihood (A) and Neighbour-joining (B) methods. 450 
Bootstrap support values of over 70% are shown. STs are indicated by differential shading. 451 
Figure 2. Analysis of M. pneumoniae using eBURST. eBURST version 3 was used to 452 
analyse the 12 unique STs resolved for all 57 M. pneumoniae isolates. Two main clonal 453 
complexes (CC) were defined. The size of each dot is proportional to the number of isolates 454 
included in the analysis for each ST. 455 
Figure 3. Prediction of recombination in the M. pneumoniae isolates chromosomes. 456 
Regions of variation in the genomes of the 35 clinical M. pneumoniae isolates and the type 457 
strain M129 which are predicted to have arisen by homologous recombination are shown in 458 
the panel on the right. Red blocks indicated recombination predicted to have occurred on 459 
internal nodes, blue indicates taxa-specific recombination). Isolates are ordered according to 460 
the phylogenetic tree displayed on the left. The track along the top of the figure displays the 461 
M129 chromosome and annotation, where protein coding sequences (CDS) are indicated in 462 
light blue. 463 
Figure 4. Distribution of MLVA, P1 type and MLST ST for 57 M. pneumoniae isolates.  464 
The 57 isolates were separated independently for MLVA type, P1 type and MLST type (each 465 
group defined by line). 466 
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